-
AbbVie’s Strategic Leap into In Vivo CAR-T with $2.1 Billion Capstan Acquisition to Transform Autoimmune Disease Treatment
Jun 30 2025 -
FDA Relaxes CAR-T Therapy Requirements, Boosting Access and Commercialization
Jun 27 2025 -
SineuGene’s SNUG01 AAV Gene Therapy Granted FDA Orphan Drug Designation for ALS
Jun 26 2025 -
Genevector’s JWK002 AAV Gene Therapy for X-Linked Retinoschisis Receives NMPA IND Approval
Jun 25 2025 -
Abeona’s COL7A1 Gene Therapy Shows Robust Efficacy in The Lancet-Published RDEB Study
Jun 24 2025 -
BioMarin’s AAV5-hFVIII-SQ Gene Therapy Shows Durable Efficacy and Safety at Five Years for Severe Hemophilia A
Jun 24 2025 -
Sangamo’s AAV Gene Therapy Shows Promising Kidney & Clinical Benefits for Fabry Disease
Jun 24 2025 -
First UK Patient Treated with CSL Behring’s AAV Gene Therapy for Hemophilia B
Jun 23 2025 -
Opus Genetics Secures $2 Million from RD Fund to Advance AAV Gene Therapy for Retinitis Pigmentosa
Jun 23 2025